Canada: SCC Confirms Leave Test For Securities Class Actions Has Teeth

On April 17, 2015, the Supreme Court of Canada provided Canadian public companies with an important win, holding that the test for leave to start a class action for breach of a company's secondary market disclosure requires the court to evaluate the evidence and conclude that there is a reasonable and realistic chance that the action will succeed. In allowing the appeal of Theratechnologies Inc. and reversing the Québec Court of Appeal's decision granting authorization of a proposed class action under s. 225.4 of the Québec Securities Act (QSA), the Court recognized that since the purpose of the leave mechanism is to screen out unmeritorious lawsuits, the test for leave must have teeth and is not simply a "speed bump" on the way to certification. Although this does not require the court to conduct a "mini-trial" or undertake a full evaluation of the evidence, the plaintiff must nonetheless provide "a plausible analysis of the applicable legislative provisions" and adduce "credible evidence in support of its claim" in order to proceed with its lawsuit. While the Supreme Court's decision was in the context of a proposed class-action under the QSA, the case has implications for public issuers across the country, as the test for leave is the same in the other provinces.


In the spring of 2010, Theratechnologies Inc. (Thera) was awaiting FDA approval of a new drug to reduce excess abdominal fat in HIV patients. As the application proceeded, Thera regularly informed its shareholders of the results of its clinical trials measuring the safety and efficacy of the drug. During the approval process, the FDA referred a number of questions about the drug, including its potential side effects, to an expert Advisory Committee, and made these questions public as part of the package of briefing materials on its website. These questions were then publicized by stock quotation enterprises, leading to a rapid drop in the price of Thera's shares. Thera did not respond publicly because it believed the briefing documents it had already provided to the FDA and the clinical trials it had already made public to its investors (which concluded that the side-effects were minor, transitory and easily managed), offered a comprehensive response to the specific questions that the FDA had posed. The plaintiff, a Thera shareholder, sought authorization to bring a class action for damages, claiming that the FDA's questions amounted to a material change in Thera's business, operations or capital, and that Thera breached its obligation to make timely disclosure of those changes under s. 73 of the QSA.

The motions judge and the Québec Court of Appeal allowed the action to proceed, finding that the claim had a "reasonable possibility of success." Thera appealed to the Supreme Court. At issue was whether the plaintiff could satisfy this second branch of the test for leave.

The Leave Test - Section 225.4 of the QSA

In Quebéc, there are two criteria that must be satisfied before the court will authorize an action for damages for breach of a company's disclosure obligations in the secondary market: (a) the action must be brought in good faith and (b) there must be a "reasonable possibility" that the action will be resolved in favour of the plaintiff. This two-pronged criteria was enacted as s. 225.4 of the QSA, and analogous provisions can be found in the Securities Acts of every province.

As Justice Abella explains in her reasons, the statutory cause of action in s. 225.4 emerged out of Canada-wide efforts to develop a more meaningful and accessible remedy for investors who have suffered a loss as a result of a breach of a company's continuous disclosure obligations.

Prior to the introduction of the statutory liability regime, Québec investors had to resort to the general rules of civil liability to obtain a remedy for a breach of a company's continuous disclosure obligations. Under the Civil Code of Québec, this meant that investors were left with the heavy burden of establishing the fault, the prejudice suffered and the causal link between the fault and the prejudice suffered. In common law jurisdictions such as Ontario, investors had to rely on the tort of negligent misrepresentation, which required that they prove reliance on the misrepresentation. Limited to these traditional causes of action, relief proved largely illusory.

The statutory liability regime reduces the burden on investors, for example, by providing a statutory cause of action without the requirement to prove reliance. At the same time, it contains a screening mechanism to weed out unmeritorious litigation. As the Supreme Court explains, the new regime "reflected an attempt to strike a balance between preventing unmeritorious litigation and strike suits and, at the same time, ensuring that investors have a meaningful remedy when issuers breach disclosure obligations."

Key Findings of the Supreme Court

s. 225.4 of the QSA vs art. 1003 CCP

Under Québec law, the commencement of a class action is governed by art. 1003 of the Code of Civil Procedure. The Supreme Court agreed with the Court of Appeal that the "reasonable possibility" criteria required under s. 225.4 of the QSA departs from the general threshold for the authorization of a class action under art. 1003 CCP. Under the latter, a simple colour of right is required. The Supreme Court reiterated that the low threshold for class actions under art. 1003 CCP reflects the dual objective of "deterrence and compensation that animate the class action system." In s. 225.4 of the QSA, however, the legislature used different language with the objective of creating a more stringent screening mechanism for securities class actions, vesting in the courts an important gatekeeping role.

A Reasonable Possibility of Success

In its judgment, the Supreme Court held that the threshold set out in s. 225.4 of the QSA requires that there be "a reasonable or realistic chance that the action will succeed." According to the Supreme Court, a case with a realistic chance of success requires the claimant to offer both a plausible analysis of the applicable legislative provisions and some credible evidence in support of the claim. Although the authorization stage under s. 225.4 of the QSA should not proceed as a mini-trial – a full analysis of the evidence is unnecessary at this stage – there must nonetheless be sufficient evidence to persuade the court that there is a realistic chance that the action will be resolved in the claimant's favour.

In this case, the plaintiff alleged that Thera failed to make timely disclosure of a material change to investors. The Act defines a material change as having two components: there must be a change in the business, operations or capital of the issuer and that change must be material (i.e., it must reasonably be expected to have a significant effect on the market price or value of the securities of the issuer). On the facts of the case, the plaintiff was unable to point to any evidence that could qualify as a change in Thera's operations, capital or business as described in the Act. The results of the clinical trials were disclosed to shareholders as they became available, and there was no new information about the side effects of the drugs that required timely disclosure when the FDA mentioned the side effects in the briefing materials. Because the evidence did not credibly point to a material change that could have triggered Thera's disclosure obligations, the Supreme Court held that there was no reasonable possibility that the action could succeed.

Implications of the Decision

The Supreme Court's interpretation of the "reasonable possibility" criterion under s. 225.4 provides important direction from the country's highest court on the applicable test under the leave criterion. Although the decision relates to the QSA, given the virtually identical language in Securities Acts across the country, it has broad-reaching implications and is clearly a "win" for public companies who face the risk of unmeritorious claims and strike suits. Given the Supreme Court's clear confirmation that the leave test is a merits-based test, in appropriate cases it will be beneficial for defendants to put forward a robust defence to leave, including through competing fact and expert evidence and cross-examination of the plaintiff's affiants.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions